Chimeras of p14ARF and p16: functional hybrids with the ability to arrest growth.

High expression of CAI2, a 9p21-embedded long noncoding RNA, contributes to advanced-stage neuroblastoma. Cancer Res (2014) 0.91

Anticarcinogenic effects of water extract of sporoderm-broken spores of Ganoderma lucidum on colorectal cancer in vitro and in vivo. Int J Oncol (2017) 0.75

The important tumor suppressor role of PER1 in regulating the cyclin-CDK-CKI network in SCC15 human oral squamous cell carcinoma cells. Onco Targets Ther (2016) 0.75

A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature (1993) 13.68

A cell cycle regulator potentially involved in genesis of many tumor types. Science (1994) 13.00

The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. EMBO J (1998) 6.08

Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature (1994) 6.06

The p16INK4a/CDKN2A tumor suppressor and its relatives. Biochim Biophys Acta (1998) 4.45

High frequency of p16 (CDKN2/MTS-1/INK4A) inactivation in head and neck squamous cell carcinoma. Cancer Res (1996) 3.18

Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas. Cancer Res (1997) 3.17

mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. Mol Cell Biol (1996) 2.78

An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo. Oncogene (2000) 2.36

Features associated with germline CDKN2A mutations: a GenoMEL study of melanoma-prone families from three continents. J Med Genet (2006) 2.17

INK4a-deficient human diploid fibroblasts are resistant to RAS-induced senescence. EMBO J (2002) 1.96

Frequent p16-independent inactivation of p14ARF in human melanoma. J Natl Cancer Inst (2008) 1.78

The CDKN2A (p16) gene and human cancer. Mol Med (1997) 1.46

Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. J Biol Chem (1996) 1.44

Sequential unfolding of ankyrin repeats in tumor suppressor p16. Structure (2003) 1.43

Prevalence of germ-line mutations in p16, p19ARF, and CDK4 in familial melanoma: analysis of a clinic-based population. Proc Natl Acad Sci U S A (1996) 1.31

A minimum folding unit in the ankyrin repeat protein p16(INK4). J Mol Biol (2000) 1.29

Compilation of somatic mutations of the CDKN2 gene in human cancers: non-random distribution of base substitutions. Genes Chromosomes Cancer (1996) 1.25

Alterations in the INK4a/ARF locus and their effects on the growth of human osteosarcoma cell lines. Cancer Genet Cytogenet (2002) 1.20

Induction of p21(WAF1/CIP1) and inhibition of Cdk2 mediated by the tumor suppressor p16(INK4a). Mol Cell Biol (1999) 1.17

Regulation of CDK4. Cell Div (2006) 1.06

Human p16gamma, a novel transcriptional variant of p16(INK4A), coexpresses with p16(INK4A) in cancer cells and inhibits cell-cycle progression. Oncogene (2007) 0.97

CDKN2a/p16INK4a mutations and lack of p19ARF involvement in familial melanoma kindreds. J Invest Dermatol (1998) 0.96

Molecular basis for complement recognition by integrin αXβ2. Proc Natl Acad Sci U S A (2012) 0.90

Mutations of the INK4a locus in squamous cell carcinomas of human skin. Biochem Biophys Res Commun (1997) 0.85

C-terminal domain of p16(INK4a) is adequate in inducing cell cycle arrest, growth inhibition and CDK4/6 interaction similar to the full length protein in HT-1080 fibrosarcoma cells. J Cell Biochem (2010) 0.82

Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. Leuk Res (1997) 0.81

Universal inactivation of both p16 and p15 but not downstream components is an essential event in the pathogenesis of T-cell acute lymphoblastic leukemia. Clin Cancer Res (2000) 0.80

A novel p16(INK4A) mutation associated with esophageal squamous cell carcinoma in a high risk population. Biomarkers (2012) 0.78

Clonal analysis of in vivo activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy. Cancer Immunol Immunother (1993) 0.78